News
Castle Biosciences Gives Long-Term Outcomes Data Shared At SSO 2024 Show That Patients With A Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free At 3-Years, Including Those Who Utilized The Test To Help Guide the Decision To Avoid An SLNB
22 Mar 24
Biotech, News, General
Castle Biosciences New Study Showing The Drug-Drug Interactions And Lifestyle Factors Provided By ' IDgenetix Test Improve Medication Recommendations Over Drug-Gene Interactions Alone For Patients 65 And Older
15 Mar 24
Biotech, News, General
Castle Biosciences To Present New Data Highlighting The Clinical Value Of Its Dermatologic Tests For Patients With Skin Cancer At The 2024 American Academy Of Dermatology Annual Meeting
8 Mar 24
Biotech, News, Events, General
Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $28
1 Mar 24
News, Price Target, Analyst Ratings
Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
1 Mar 24
News, Price Target, Analyst Ratings
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Thursday's Intraday Session
29 Feb 24
Movers
Recap: Castle Biosciences Q4 Earnings
28 Feb 24
Earnings
Castle Biosciences Q4 2023 GAAP EPS $(0.10) Beats $(0.61) Estimate, Sales $66.12M Beat $56.28M Estimate
28 Feb 24
Earnings, Earnings Beats, News
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Earnings Preview For Castle Biosciences
27 Feb 24
Earnings
Press releases
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
11 Apr 24
Press Releases
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
10 Apr 24
Press Releases
Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
4 Apr 24
Press Releases
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Press Releases
Castle Biosciences Announces Updates to its Board of Directors
27 Mar 24
Press Releases
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
25 Mar 24
Press Releases
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
22 Mar 24
Press Releases
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
15 Mar 24
Press Releases
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
12 Mar 24
Press Releases
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
8 Mar 24
Press Releases
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
7 Mar 24
Press Releases